GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

ContraFect CFRXQ · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

ContraFect — daily CFRXQ Delayed
Market value
$11
Last close × shares
Volume
3k
Shares, 9 Nov 2026

About ContraFect

Its shares trade under the ticker CFRXQ. It has been listed since 29 July 2014.

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

Figures and description from our data supplier, not checked against the company's own report.

More about ContraFect →

Latest on ContraFect

Our reporting

We have not reported on ContraFect yet.

Next results

16 Nov 2026

Due on 16 Nov 2026. Analysts expect earnings of -23.60 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is ContraFect's ticker?

ContraFect trades as CFRXQ on its US listing, under ISIN US2123264093.

What was ContraFect's last closing price?

0.00 on 9 Nov 2026. The figure is in USD and is never converted.

When does ContraFect next report results?

Results are expected on 16 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.